GSK2636771: A Potent and Selective PI3K Beta Inhibitor for Cancer Research and Development
Discover the power of GSK2636771, a highly selective PI3K beta inhibitor designed to advance cancer research and targeted therapy development. Learn about its mechanism, applications, and benefits for pharmaceutical innovation.
Get a Quote & SampleProduct Core Value
GSK2636771
As a leading pharmaceutical intermediate supplier in China, we offer GSK2636771, a potent and orally bioavailable inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform. This compound is crucial for research into cancer therapies, particularly for PTEN-deficient tumors. Its high selectivity and proven efficacy in preclinical models make it an invaluable asset for drug discovery and development.
- Explore the potential of GSK2636771 for targeted cancer therapy, a key application of selective PI3K beta inhibitors.
- Understand the mechanism of GSK2636771 in preclinical studies, demonstrating its effectiveness in inhibiting tumor cell migration and invasion.
- Leverage GSK2636771 for PI3K pathway research, a critical area in understanding and treating various cancers.
- Incorporate GSK2636771 into your drug development pipeline for advanced oncology treatments.
Advantages Offered by GSK2636771
Unmatched Selectivity
GSK2636771 offers superior selectivity, providing a powerful tool for researchers investigating the specific roles of PI3K beta in cellular processes and disease.
Oral Bioavailability
Its oral bioavailability enhances its utility in preclinical and potential clinical applications, simplifying administration in targeted therapy studies.
Efficacy in PTEN-Deficient Cancers
GSK2636771 demonstrates significant activity against PTEN-deficient cancer cells, making it a promising candidate for precision medicine approaches.
Key Applications
Oncology Research
Utilize GSK2636771 for in-depth studies of PI3K pathway dysregulation in various cancer types, aiding in the discovery of novel therapeutic targets.
Drug Development
Incorporate this selective PI3K beta inhibitor into your pharmaceutical development programs to create next-generation cancer treatments.
Targeted Therapy
GSK2636771 is instrumental in developing targeted therapies that precisely address specific molecular alterations in cancer cells, improving treatment outcomes.
Preclinical Studies
Employ GSK2636771 in preclinical models to evaluate its efficacy and safety profile for potential clinical translation in oncology.